Colorado BioScience Association

06/05/2026

Congratulations to Founder & CEO, Rose Nash, PhD, and the team at Biota Inc. on the opening of your new 7,500-square-foot laboratory and innovation facility in Longmont.

The new facility will support continued development, validation, and commercialization of Biota’s PFAS monitoring platforms, as well as growth of its scientific and engineering team in Colorado.

"Biota represents the science-driven innovation that defines Colorado's life sciences leadership," said Elyse Blazevich, President and CEO of Colorado BioScience Association. "Their work developing faster and more scalable PFAS monitoring technologies demonstrates how Colorado companies transform breakthrough science into solutions that save and change lives in our state and around the world."

We look forward to your continued success!

Read more: https://www.prnewswire.com/news-releases/colorado-pfas-testing-company-biota-opens-longmont-innovation-facility-amid-growing-demand-for-faster-forever-chemical-monitoring-302789626.html

/PRNewswire/ -- As states, utilities, and environmental teams face growing pressure to monitor and respond to PFAS contamination, Colorado-based environmental...

06/04/2026

Member Success: CBSA congratulates three Colorado companies accepted into MedTech Innovator (MTI) 2026 accelerator cohort:

- ForCast Orthopedics, Inc
- GenesisTissue Inc.
- TissueForm, Inc.

Over the next four months, the 65 companies in the cohort will receive world-class mentorship, strategic guidance, and unparalleled access to MTI's ecosystem of investors, health systems, and industry leaders. They'll also compete for a share of over $1.3M in funding.

We look forward to their continued success!

06/04/2026

Member Success: Colorado BioScience Association congratulates CBSA member companies Biota Inc., Codebreaker Labs, GenesisTissue Inc., and Intero Biosystems on receiving Advanced Industries Accelerator Grants from the Colorado Office of Economic Development and International Trade.

We also applaud innovators from CBSA’s partner academic and research institutions, including University of Colorado Boulder, University of Colorado Denver, and Colorado School of Mines, who received grant funding to advance promising technologies.

Colorado’s Advanced Industries Accelerator Grant Program continues to deliver powerful results for innovation and economic growth. Since inception, the program has awarded $188.1 million, helped generate $4.3 billion in follow-on capital, and delivered an impressive $22.08 return for every $1 invested.

Strategic state investments strengthen Colorado’s competitiveness by supporting the R&D-intensive industries driving our economy and advancing solutions that save and change lives. Congratulations to all grantees!

DENVER - Today, the Global Bus

06/02/2026

Last week, CBSA members, staff, and lobbyists met with Colorado Attorney General and gubernatorial candidate Phil Weiser. This valuable touchpoint before the primary election with AG Weiser included discussions about the impact of life sciences across Colorado and allowed CBSA members to share perspectives on key issues affecting innovation, healthcare, workforce, and economic growth in our state.

The meeting was also a critical opportunity for CBSA members to share concerns about the artificial intelligence bill recently passed by Colorado’s General Assembly. AG Weiser indicated that, whether he continues as Attorney General or is elected Colorado’s next governor, he wants to do what he can to make sure some of those concerns are addressed during the upcoming rulemaking process.

Shown in Photo:

Meg Porfido - Phil Weiser for Colorado
Amy Berenbaum Goodman, JD, MBE - Vice President and Counsel, Policy + Advocacy, CBSA
Amy Friedman - Community Engagement Lead, Phil Weiser for Colorado

Row 2:
Elyse Blazevich - President & CEO, CBSA
Rita “Ruta” Sanzgiri, Ph.D. - Intellectual Property Attorney, CBSA Board Secretary and Community Growth & Engagement Committee Chair
Matthew Teter - Vice President of Partnerships, CBSA

Row 3:
Byron Hewett - Life Sciences Executive & Strategic Advisor, CBSA Board Chair
Jenny Nikaido - Community & State Government Relations Sr. Specialist, Terumo Blood and Cell Technologies
Jason Tejani - SVP, Head of Legal, Enveda

Row 4:
Zoey Powers - Senior Director, State Government Affairs, Eli Lilly and Company
Melanie Layton - Co-Owner, Lobbyist, Colorado Legislative Strategies
Robin Harper Cowie - Chief Financial Officer, Biodesix, Inc., CBSA Board Vice Chair

Row 5:
Nate Myszka - Director, State Government Affairs, Medtronic
Caroline Woodhouse - Lobbyist, Colorado Legislative Strategies
Phil Weiser - Colorado Attorney General & Gubernatorial Candidate

05/27/2026

Detecting cancer earlier improves patient outcomes and saves lives. Today, Colorado BioScience Association celebrated the passage of the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection (MCED) Screening Coverage Act, one of our longtime federal policy priorities. The new law, passed by Congress earlier this year, provides Medicare coverage and payment for FDA-approved multi-cancer early detection screening tests.

It was an honor to mark the passage of this landmark bipartisan legislation with Senate sponsor Senator Michael Bennet, Colorado Gynecologic Cancer Alliance, One Cancer Place, Colorado Gerontological Society, Western States Cancer Research, Chronic Care Collaborative, Fitzsimons Innovation Community, and patient advocates.

Shown in Photos:

Senator Michael Bennet

Elyse Blazevich, President & CEO, Colorado BioScience Association

Patriece Hauptman, Executive Director of the Colorado Gynecologic Cancer Alliance

Kelly Brough, President & CEO, Fitzsimons Innovation Community

Chief John Curtis, South Metro Fire Rescue

Erika Hansen Brown, CEO & Founder of One Cancer Place

Speakers emphasized the importance of policymakers, health innovators, patient advocates, and employers working together to ensure patient access to tools and technologies for early cancer detection.

05/21/2026

Colorado BioScience Association congratulates the 2026 Class of Boettcher Investigators!

Each of the eight scientists will receive a $250,000 grant through the Boettcher Foundation’s Webb-Waring Biomedical Research Awards Program to fund up to three years of independent scientific research, with total grant funding reaching $2 million.

This year’s class represents the next generation of scientific excellence and marks another milestone in Boettcher Foundation’s 17-year commitment to strengthening Colorado’s biomedical research ecosystem. The Webb-Waring Biomedical Research Awards provide critical early-career support and position recipients to compete for additional private, state, and federal research funding while helping Colorado retain top scientific talent. Meet the 2026 Class of Boettcher Investigators (Shown L-R):

COLORADO STATE UNIVERSITY
Casey M. Gries, Ph.D
R. Adam Harris, D.V.M., Ph.D., Diplomate ACVP

NATIONAL JEWISH HEALTH
Chen-Shan (Julia) Woodcock, Ph.D.

UNIVERSITY OF COLORADO ANSCHUTZ
Alessandra Brambati, Ph.D.
John Janetzko, Ph.D.
Katherine Kissler, C.N.M., Ph.D.
Kentaro Yomogida, M.D.
UNIVERSITY OF COLORADO BOULDER
Matthew Olm, Ph.D.

“Colorado’s future as a leading hub for health innovation depends on bold scientific thinking and sustained investment in emerging researchers,” said Elyse Blazevich, president and CEO of Colorado BioScience Association. “The Boettcher Investigators are advancing high-impact discoveries across some of the most urgent challenges in human health while strengthening Colorado’s position as a center for biomedical research and innovation. These awards help accelerate breakthrough science, support exceptional talent, and reinforce the collaborative research environment that sets Colorado apart.”

More: https://cobioscience.com/boettcher-foundation-awards-2-million-to-advance-the-groundbreaking-research-of-early-career-scientists/

05/05/2026

What an afternoon! Colorado’s life sciences leaders came together in record numbers to build relationships and shape the future of life sciences in our state at CBSA’s All Member Meeting + Networking event in Boulder last week.

Members engaged in vibrant conversations, forged new relationships, and explored ways to strengthen and grow our collaborative ecosystem, as we work toward becoming a top five U.S. hub for health innovation.

Thank you to our table exhibitors for helping spark so many meaningful connections:

Bank of America
Colorado BioScience Institute
Fisher Scientific
Fitzsimons Innovation Community
Higginbotham
Innosphere
TEConomy Partners

CBSA extends a special thanks, as well, to the St. Julien Hotel in Boulder for hosting our community and to our 2026 All Member Meeting sponsors: Bank of America, BioMed Realty, BNBuilders, Cooley LLP, Fisher Scientific, Fitzsimons Innovation Community, Higginbotham, PhRMA, SOMALOGIC LIMITED, Terumo Blood and Cell Technologies, and Umoja Biopharma, for making this event possible.

05/01/2026

Colorado’s life sciences community showed up in full force to connect, collaborate, and shape what’s next for our ecosystem at CBSA’s annual All Member Meeting + Networking event in Boulder. Thank you to our members and sponsors for turning out in record numbers! It was a standing-room-only crowd.

CBSA President and CEO Elyse Blazevich kicked off the energetic afternoon, highlighting the ecosystem’s early fundraising momentum in 2026 after hitting a new high in 2025 with $3.2B raised. She emphasized Colorado’s top 20 ranking for life sciences R&D, and recognized companies choosing Colorado for their next phase of growth.

CBSA’s incoming Board of Directors Chair, Byron Hewett, highlighted the board’s vision for the Colorado Life Sciences Strategic Roadmap. This comprehensive initiative will identify our state’s strengths, pinpoint key growth opportunities, and inform priority areas for investment. He led a dynamic panel discussion providing early insights on the roadmap research and development. CBSA Board of Directors members, April Giles of End Drug Shortages Alliance and Kevin Noble of Innosphere, were joined by executives from TEConomy Partners, a leading consulting firm in innovation-driven economic development selected by CBSA to develop the strategic roadmap.

TEConomy’s Ryan Helwig, Joe Simkins, and Jonathan Dworin emphasized the richness and depth of resources across Colorado’s life sciences ecosystem. Panelists and audience members shared insights on Capital + Growth, support for early-stage companies, Colorado’s exceptional talent, and opportunities to unite stakeholders as we build a comprehensive, statewide life sciences strategy. Attendees contributed to the research by participating in a live survey designed to inform roadmap development.

CBSA extends a special thanks to the St. Julien Hotel in Boulder for hosting our community and to our 2026 All Member Meeting sponsors: Bank of America, BioMed Realty, BNBuilders, Cooley LLP, Fisher Scientific, Fitzsimons Innovation Community, Higginbotham, PhRMA, SOMALOGIC LIMITED, Terumo Blood and Cell Technologies, and Umoja Biopharma, for making this event possible.

04/23/2026

Senator Michael Bennet met with leaders of Foresight Diagnostics (a Natera company) and Colorado BioScience Association Vice President and Counsel for Policy + Advocacy Amy Berenbaum Goodman, JD, MBE in Boulder last week.

The conversations covered Foresight's leadership in diagnostics and the importance of legislation at the federal and state level to expand reimbursement and insurance coverage for next-generation diagnostics.

CBSA thanks the Foresight Diagnostics and Natera teams for the tour and insightful conversations.

Read more about Foresight's growth in Colorado in our BioScience Colorado Magazine: https://cobioscience.com/flipbooks/11/flipbook/?page=28

04/17/2026

Join the Colorado BioScience team!

Colorado BioScience Institute is seeking an Executive Director to lead the next chapter of its mission to cultivate and diversify Colorado’s life sciences workforce, from classroom, to campus, to career.

This senior leadership role provides full organizational leadership, owning strategy, and ex*****on for the Institute. The Executive Director is accountable for the Institute’s fundraising strategy and results, while overseeing partnerships, programs, and operations to ensure strong organizational performance and impact.

This is a unique opportunity for an experienced nonprofit leader motivated to scale a growing organization, strengthen its infrastructure, and expand impact across Colorado’s life sciences ecosystem.

Apply today: https://careers.cobioscience.com/job/3479/executive-director/